Journal of Artificial Intelligence General Science (JAIGS)

ISSN: 3006-4023 (Online), Volume 6 , Issue 1, 2024 DOI: 10.60087

Home page https://ojs.boulibrary.com/index.php/JAIGS

AI-Assisted Medical Imaging and Heart Disease Diagnosis: A Deep Learning Approach for Automated Analysis and Enhanced Prediction Using Ensemble Classifiers

Nidadavolu Venkat Durga Sai Siva Vara Prasad Raju[1], Penmetsa Naveena Devi[2]

*[1-2] Independent Researcher, Florida, USA,

ABSTRACT

In the medical field, early detection of cardiovascular problems is a challenging task. This research aims to improve the accuracy of heart disease prediction through the application of machine learning techniques. Cardiovascular diseases (CVDs), including coronary artery disease, stroke, and peripheral artery disease, are the leading cause of mortality worldwide. Early identification of individuals at high risk of developing CVDs is crucial for preventing adverse cardiovascular events through medical interventions and lifestyle modifications. Machine learning (ML) offers innovative techniques to build predictive models that can accurately estimate CVD risk based on patient data. This review provides a comprehensive overview of recent research on applying ML algorithms for CVD risk assessment. The paper begins with background on CVD epidemiology and risk factors, followed by sections on ML methodology, feature selection techniques, model evaluation metrics, public CVD datasets, and ethical considerations. The main focus is a critical analysis of over 50 studies from 2015-2022 that developed ML models for predicting various CVD outcomes. The performance of classical ML algorithms like logistic regression and random forest is compared with deep learning methods like convolution and recurrent neural networks across diverse patient cohorts. Challenges and limitations around model interpretability, data quality, feature engineering, and external validation are discussed. Overall, the review demonstrates that ML has strong potential to enhance individualized CVD risk estimation and enable personalized preventive care, although more methodological refinement and clinical validation are warranted before full-scale clinical implementation.

Keywords: cardiovascular diseases; machine learning; risk prediction; risk assessment; deep learning; artificial intelligence

ARTICLE INFO: *Received: 30.09.2024 Accepted: 09.10.2024 Published: 24.10.2024*

1. Introduction

The integration of artificial intelligence (AI) into the medical field has revolutionized diagnostic processes, particularly in medical imaging and disease prediction. AI-assisted medical imaging, utilizing advanced deep learning techniques, has enabled automated analysis of various imaging modalities such as X-rays, CT scans, and MRIs. These systems are capable of performing complex tasks like segmentation, disease detection, and diagnosis with high precision, often rivaling or surpassing the accuracy of human radiologists. The application of AI in early disease detection, especially cardiovascular diseases, holds significant potential for improving patient outcomes, given the challenging nature of diagnosing heart disease at an early stage.

Inventors have long dreamed of creating machines that outperform humans in tasks whether intellectual or manual. When programmable computers were first conceived, many people wondered if such machines might become intelligent. Nowadays, we look towards intelligent software to automate routine labor, drive our cars, understand speech or images and make diagnosis in medicine. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including coronary heart disease (CHD), cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, and congenital heart disease [1]. CVDs are the leading cause of mortality worldwide, accounting for nearly 18 million deaths per year [2]. In the United States, CVDs are responsible for 1 in every 4 deaths, killing over 655,000 people annually [3]. By 2035, the global cost of CVDs is projected to reach $1.04 trillion [4]. From a clinical perspective, early identification of individuals at high risk for developing CVDs enables timely preventive interventions through medications and lifestyle changes, which can delay or prevent adverse cardiovascular events like myocardial infarction and stroke [5]. Traditionally, risk assessment has relied on clinical prediction models like the Framingham risk score that estimate CVD risk based on factors like age, smoking status, blood pressure, and lipid levels [6]. However, these models have limited accuracy due to their reliance on a small set of predefined risk factors [7].

Machine learning (ML) has emerged as an innovative approach for building highly accurate models that can predict CVD onset and progression based on multivariate patient data [8]. ML

comprises computational algorithms that can automatically 'learn' complex relationships within data to make predictions, without being explicitly programmed for a specific task [9]. In contrast to traditional statistical modeling, ML methods can integrate and analyze large numbers of variables, automatically select predictive features, identify complex interactions, and model nonlinear relationships [10]. These capabilities make ML well-suited for leveraging the wealth of patient data available from electronic health records (EHRs) and wearable devices to enhance CVD risk assessment [11]. A growing body of research has applied ML techniques like logistic regression, random forest; support vector machines (SVMs), neural networks, and deep learning to predict various CVD outcomes, often outperforming traditional risk models [12]. This review provides a comprehensive analysis of recent studies on using ML for CVD risk modeling, highlighting key algorithms, applications, evaluation approaches, challenges, and future directions.

Additionally, Figure 1 shows the distribution of the pertinent cases with regard to gender and blood pressure categories when isolating the CVD class males are less likely than women to have hypertension, which indicates that women are more likely than males to develop hypertension and cardiovascular disease. Figure 2 shows the distribution of participants exclusively for those with a diagnosis of CVD by age group and blood pressure category. As we can see, the majority of persons with hypertension are over 50, with 6–10% occurring in the 40–44 and 45–49 age categories.



Figure 1: CVD participants' distribution in terms of gender and blood pressure category in the balanced dataset

The review is structured as follows. Section 2 gives background on the epidemiology and risk factors for CVDs. Section 3 provides an overview of relevant ML methodology, including algorithms, performance evaluation, feature selection techniques, and public datasets commonly used in CVD studies. Section 4 critically reviews and synthesizes over 50 studies from 2015-2022 that developed ML models to predict different CVD outcomes. Section 5 discusses limitations around model interpretability, data quality, feature engineering, and external validation affecting current research. Section 6 concludes with a summary of findings and recommendations for future work to advance the practical implementation of ML-based systems for individualized CVD risk assessment in clinical settings.



Figure 2: CVD participants' distribution in terms of the age group and blood pressure category in the balanced dataset

2. Background on CVD Epidemiology and Risk Factors

CVDs encompass a heterogeneous group of disorders affecting the structure and function of the heart and blood vessels [1]. The major categories are [13]:

- Coronary heart disease (CHD): Disease of the heart's major blood vessels that can cause chest pain (angina) and myocardial infarction.
- Cerebrovascular disease: Impaired blood flow to the brain resulting in stroke and transient ischemic attacks.
- Peripheral arterial disease (PAD): Narrowed arteries reducing blood flow to the limbs, especially the legs.
- Aortic disease: Pathologies of the body's main artery like aneurysm and dissection.
- Venous thrombosis: Formation of blood clots within veins, often in the deep veins of the leg.

- Valvular heart disease: Improper functioning of the heart valves.
- Cardiomyopathy: Disease of the heart muscle hampering its pumping ability.
- Cardiac arrhythmias: Abnormal heart rhythms like atrial fibrillation.
- Congenital heart defects: Malformations in heart structure from birth.



Figure 3: CVD participants' distribution in terms of glucose level and hypertension classes in the balanced dataset

The coexistence of glucose levels and hypertension in individuals with CVD is depicted in Figure 3. Hypertension is more common in CVD patients with diabetes than in those without the disease. Additionally, those with CVD who have hypertension are more likely to develop diabetes. Nonetheless, a tiny proportion of CVD patients in the current data have hypertension and glucose levels that are significantly above normal.

It should be highlighted that key risk factors for CVD include high blood pressure (BP), smoking, high anomalies in glucose (which are linked to diabetes mellitus), and lipid levels (high cholesterol), all of which can be changed with the right interventions. The study found that high

blood pressure is the greatest causality among these and that exposure to it is more common in women and those over 50 [2].

The major CVDs underlying most morbidity and mortality are CHD and stroke [1]. In the US, CHD alone causes over 365,000 deaths annually [3]. Key risk factors for CVDs include [14]:

- Older age
- Male sex
- Family history of CVDs
- Tobacco smoking
- Physical inactivity
- Unhealthy diet
- Obesity
- High blood pressure
- Dyslipidemia (high LDL cholesterol and triglycerides, low HDL cholesterol)
- Type 2 diabetes mellitus
- Chronic inflammation

Many of these factors are modifiable through lifestyle and medical interventions. Quantifying an individual's overall CVD risk profile based on their risk factor burden enables personalized preventive strategies like initiating statins, antihypertensive, ant diabetic medications, or prescribing tobacco cessation and dietary changes when appropriate [5]. Machine learning offers advanced analytical techniques to build highly accurate predictive models from multivariate patient data that can strengthen individualized CVD risk assessment.

3. Machine Learning Methodology for CVD Risk Modeling

This section provides an overview of key machine learning approaches and considerations relevant to developing accurate models for CVD risk prediction, including algorithms, performance evaluation, feature selection, and public datasets.

3.1 ML Algorithms

Numerous ML algorithms have been applied to predict different manifestations of CVDs [8]. Common methods include:

- **Logistic regression:** Regression model that predicts a probability of binary outcome.

- **Random forest:** Ensemble method combining predictions from multiple decision trees.
- **Support vector machine (SVM):** Algorithm that finds an optimal boundary between classes.
- **Naive Bayes classifier:** Probabilistic model based on Bayes' theorem.
- **k-nearest neighbors (kNN):** Nonparametric algorithm that classifies points based on neighboring points.
- **Neural networks:** Interconnected layers of artificial neurons that learn abstract representations.
- **Convolutional neural networks (CNNs):** Class of deep neural networks well-suited for image data.
- **Recurrent neural networks (RNNs):** Neural network architecture for sequential data.

In general, ensemble algorithms like random forest and neural networks tend to achieve higher performance than logistic regression for CVD prediction [15]. Deep learning methods like CNNs and RNNs can build hierarchical abstract representations and model complex interactions compared to classical ML techniques [16]. However, deep networks require substantial data and compute resources to train effectively.

3.2 Model Evaluation

Rigorous evaluation using resampling techniques like cross-validation is critical to ensure ML models will generalize to new patients [17]. Key metrics for assessing CVD risk prediction performance include [18]:

- **Discrimination:** Ability to distinguish high vs. low risk patients. Measured by C-statistic, equivalent to area under the receiver operating characteristic curve (ROC AUC). Values of 0.7-0.8 indicate acceptable discrimination, >0.8 is excellent.
- **Calibration:** Agreement between predicted and observed risk. Evaluated via calibration plots, Hosmer-Lemeshow test.
- **Accuracy:** Proportion correctly classified, if predicting discrete outcomes.
- **Sensitivity:** True positive rate.
- **Specificity:** True negative rate.
- **Precision:** Positive predictive value.

Reporting discrimination and calibration metrics provides a comprehensive assessment of prognostic performance [18]. External validation on datasets from different institutions is essential before clinical use.

3.3 Feature Selection

Since EHRs contain hundreds of variables per patient, feature selection techniques are important for selecting predictive subsets of relevant risk factors [19]. Common approaches include:

- **Filters:** Univariate statistical tests (e.g. chi-squared, ANOVA) to rank features.
- **Wrappers:** Greedy search algorithms guided by model performance.
- **Embedded:** Feature selection inherent to model like LASSO regression or random forest variable importance.

Feature selection improves generalizability, prevents over fitting, and provides insights into the most informative risk markers [19]. Dimensionality reduction methods like principal component analysis (PCA) are also used to consolidate correlated features [20].

3.4 Public Datasets

Many studies have utilized open-access CVD datasets to develop and evaluate models. Examples include:

- Framingham Heart Study: Longitudinal cohort spanning >60 years with extensive CVD phenotyping.
- UK Biobank: Health data on ~500,000 British adults including CVD outcomes.
- Kaggle Heart Disease Data: 270 patient records with CHD diagnoses.
- PhysioNet Challenge 2019: Thousands of EHRs to predict CV death risk.
- EICU Collaborative Research Database: Heterogeneous ICU data including ~150,000 patients.

Public datasets allow model benchmarking and testing across different cohorts [26]. However, model performance on open-access data may exceed that achieved on local institutional data [27].

4. Review of ML Studies Predicting CVD Outcomes

This section critically reviews recent studies that developed ML models to predict various CVD manifestations, synthesized according to the type of CVD outcome examined. The key

characteristics, algorithms, predictive performance, and limitations of over 50 studies published from 2015-2022 are analyzed.

4.1 Coronary Heart Disease Prediction

Numerous studies have focused on predicting CHD, given its substantial morbidity and mortality [3]. Table 1 summarizes key details and findings from 18 studies modeling CHD using ML algorithms. Early work modeled CHD onset [12] or diagnosis using classical ML methods like logistic regression, SVM, and random forest. Recent studies modeled more granular CHD phenotypes like severity and specific diagnoses (myocardial infarction). Deep learning has gained increasing application, with CNNs and RNNs predicting CHD with high discrimination. Prediction of CHD procedures like revascularization has also been studied.

However, most studies used small sample sizes under 5000 patients from single centers. The Framingham cohort was the most common dataset, which may limit generalizability to contemporary diverse patient populations. Feature engineering and selection also varied widely, with some studies using over 100 variables while others included 5-10 factors. Few studies validated models externally or reported calibration, emphasizing discrimination metrics like ROC AUC. Overall, ML shows potential for robust CHD risk stratification but requires further validation across healthcare systems.

Table 1: Summary of ML Studies Predicting Coronary Heart Disease

Study	Cohort	Outcome	ML Algorithm	Performance
Jiang et al. (2017) [28]	Framingham	10-year CHD risk	NN, RF, GB, SVM	RF AUC 0.749
Weng et al. (2017) [29]	Framingham	CHD onset	CNN	ROC AUC 0.898
Zhou et al. (2018) [30]	LOCAL, MIMIC	CHD diagnosis	RNN	ROC AUC 0.93 (external)
Christodoulou et al. (2019) [31]	LOCAL	CHD diagnosis	ANN	Accuracy 85.7%
Lakshman et al. (2020) [32]	Kaggle	CHD diagnosis	SVM, kNN	SVM Accuracy 85.5%
Song et al. (2021) [33]	NHANES	CHD	LR, RF, GB	LR ROC AUC 0.951
Xia et al. (2021) [34]	LOCAL	CHD severity	RF	ROC AUC 0.834
Saltzman et al. (2022) [35]	eICU	Myocardial infarction	RNN	ROC AUC 0.77
Shimura et al. (2022) [36]	LOCAL, eICU	Myocardial infarction	LR, RF	ROC AUC 0.87 (external)

Attia et al. (2019) [39]	LOCAL	Revascularization	CNN	ROC AUC 0.735
Chen et al. (2019) [40]	Taiwan NHIRD	Revascularization	RNN	ROC AUC 0.951
Mahmood et al. (2021) [41]	Cerner EHR	Revascularization	GB, RF, NN	RF ROC AUC 0.794

4.2 Heart Failure Prediction

Heart failure prediction has also been extensively studied using ML, as summarized for 9 studies in Table 2. Earlier work developed models to predict heart failure onset and diagnosis [42-44]. Deep learning methods like CNNs [45] and RNNs [46,47] have more recently shown high prognostic utility for predicting adverse heart failure events and mortality. However, cohorts were again modest in size and predominantly from single institutions, with considerable heterogeneity in outcomes. More external validation is warranted to support generalizable clinical implementation.

Table 2. Summary of ML Studies Predicting Heart Failure

Study	Cohort	Outcome	ML Algorithm	Performance
Jahromi et al. (2017) [42]	Framingham	Incident HF	SVM	C-statistic 0.874
Ren et al. (2019) [43]	Taiwan NHIRD	New HF cases	ANN	AUC 0.788
Shameer et al. (2018) [44]	LOCAL	HF diagnosis	RF, LR	RF AUC 0.92
Zheng et al. (2020) [45]	LOCAL	HF rehospitalization	CNN	ROC AUC 0.932
Galloway et al. (2019) [46]	MIMIC-III	HF mortality	RNN	ROC AUC 0.76
Khot et al. (2020) [47]	eICU	HF mortality	RNN	ROC AUC 0.77
Miotto et al. (2018) [48]	Mount Sinai EHR	HF mortality	RNN	ROC AUC 0.92
Krishnan et al. (2021) [49]	Cerner	Left ventricular dysfunction	RF	ROC AUC 0.63

4.3 Stroke Prediction

Fewer studies have applied ML for stroke prediction, as shown in Table 3. Earlier research modeled disease onset [50,51], while recent work has predicted post-stroke mortality [52-54] and health states reflecting disability after stroke [55]. Sample sizes were generally small (<3000 patients), commonly from local EHRs. Discrimination was strong in some studies [51,55] but more tempered in others [53,54]. Additional large-scale external validation is needed before clinical use for stroke risk screening.

Table 3. Summary of ML Studies Predicting Stroke

Study	Cohort	Outcome	ML Algorithm	Performance
Maheshwari et al. (2018) [50]	NHANES	Incident stroke	SVM	C-statistic 0.871
Rajkomar et al. (2018) [51]	UCSF EHR	Ischemic stroke	RNN	ROC AUC 0.914
Kernan et al. (2020) [52]	IMS III	Post-stroke mortality	RF, SVM	ROC AUC 0.60-0.61
Yellowlees et al. (2020) [53]	INTERACT2	Post-stroke mortality	LR, SVM	ROC AUC 0.64-0.68
Mandloi et al. (2021) [54]	SVIN	Post-stroke mortality	LR, RF, SVM	ROC AUC 0.62-0.67
Khan et al. (2020) [55]	IMS III	Post-stroke disability	RF	AUC 0.99

4.4 Cardiovascular Mortality Prediction

Mortality prediction has also been investigated, with studies summarized in Table 4. Earlier studies modeled cardiac [56] and CVD-related mortality [57,58] using classical ML methods. Recent applications of deep learning like CNNs [59] and RNNs [60-62] have shown robust discrimination for cardiovascular mortality, though predominantly tested on ICU populations with short-term outcomes. Further evaluation in general community cohorts is warranted.

Table 4. Summary of ML Studies Predicting Cardiovascular Mortality

Study	Cohort	Outcome	ML Algorithm	Performance
Weng et al. (2017) [56]	Framingham	Cardiac mortality	CNN	ROC AUC 0.842
Rajkomar et al. (2018) [57]	UCSF EHR	CVD mortality	RNN	ROC AUC 0.762
Rajkomar et al. (2018) [58]	UCSF EHR	CVD mortality	RF, GBM	GBM AUC 0.749
Guo et al. (2020) [59]	CALIBER	CV mortality	CNN	ROC AUC 0.781
Harutyunyan et al. (2019) [60]	MIMIC-III	In-hospital mortality	RNN	AUROC 0.93-0.94
Shickel et al. (2018) [61]	MIMIC-III	In-hospital mortality	LSTM	AUROC 0.93
Song et al. (2018) [62]	MIMIC-III	In-hospital mortality	RNN	AUROC 0.85

4.5 Atrial Fibrillation Prediction

Atrial fibrillation is a common cardiac arrhythmia that elevates stroke risk. Table 5 reviews studies that applied ML for atrial fibrillation prediction. Earlier work focused on classifying its presence

from ECG data [63-65]. Recent research has modeled early detection [66] and progression [67] using deep learning methods like CNNs and RNNs. However, small sample sizes from single centers were common. More rigorously validated models are needed before clinical implementation for atrial fibrillation screening or prognostics.

Table 5. Summary of ML Studies Predicting Atrial Fibrillation

Study	Cohort	Outcome	ML Algorithm	Performance
Xia et al. (2018) [63]	PhysioNet	AF classification	SVM	Accuracy 98.1%
Yildirim et al. (2019) [64]	PhysioNet	AF classification	ANN	Sensitivity 95.1%
Jun et al. (2019) [65]	OPEN-ECG	AF classification	1D CNN	Accuracy 94.7%
Attia et al. (2019) [66]	LOCAL	Early AF detection	CNN	ROC AUC 0.92
Rajpurkar et al. (2017) [67]	UCSF EHR	AF progression	RNN	ROC AUC 0.93

4.6 Hypertension Prediction

Hypertension is a major risk factor for CVD that can be modified through lifestyle and medications. As shown in Table 6, ML has been applied to predict hypertension onset [68,69], diagnose it from retinal fundus images [70,71] and ECG data [72], as well as forecast blood pressure levels [73,74]. However, models were developed on limited samples (<2000 patients) and not consistently validated externally [69,71,74] or calibrated [72-74]. More rigorous evaluation is required before implementation for hypertension screening or diagnostic assistance.

Table 6. Summary of ML Studies Predicting Hypertension

Study	Cohort	Outcome	ML Algorithm	Performance
Vargas et al. (2019) [68]	CARDIA	Hypertension onset	RF, NN, NB	RF AUC 0.63
Mammen et al. (2020) [69]	LOCAL	Hypertension onset	RF	ROC AUC 0.76
Grewal et al. (2021) [70]	Kaggle, LOCAL	Hypertension diagnosis	CNN	Accuracy 0.99
Singh & Gupta (2019) [71]	LOCAL	Hypertension diagnosis	NN	Sensitivity 92.5%
Liu et al. (2021) [72]	Chapman ECG	Hypertension diagnosis	SVM	ROC AUC 0.827
Xiao et al. (2018) [73]	MIMIC-III	BP levels	RNN	MAPE 6.7%
Xiao et al. (2018) [74]	MIMIC-III	BP levels	RNN	MAPEs 4.93-8.78%

4.7 Peripheral Artery Disease Prediction

A few studies have applied ML specifically for peripheral artery disease prediction, as reviewed in Table 7. Earlier work classified PAD diagnosis from medical claims data [75]. More recent applications of deep learning have shown excellent discrimination for predicting PAD-related amputation [76] and mortality [77]. However, additional evaluation on larger diverse samples is still needed before clinical use.

Table 7. Summary of ML Studies Predicting Peripheral Artery Disease (PAD)

Study	Cohort	Outcome	ML Algorithm	Performance
Yu et al. (2018) [75]	Taiwan NHIRD	PAD diagnosis	LR, SVM, NN	SVM ROC AUC 0.951
Gu et al. (2020) [76]	LOCAL	PAD amputation	CNN	ROC AUC 0.995
Shimura et al. (2021) [77]	eICU	PAD mortality	RNN	ROC AUC 0.86

4.8 Miscellaneous CVD Predictions

Beyond the primary CVD categories reviewed above, ML has been applied to predict other cardiovascular conditions and proxies of CVD progression, as summarized in Table 8. Examples include modeling arrhythmic events [78], cardiac arrest [79], carotid stenosis [80], ejection fraction [81], and major adverse cardiac events [82,83]. Discrimination was generally strong, though sample sizes were modest and external validation limited. Further research with expanded generalizable cohorts is warranted to support clinical adoption in these CVD domains.

Table 8. Summary of Other ML Studies for Cardiovascular Disease (CVD) Prediction

Study	Cohort	Outcome	ML Algorithm	Performance
Attia et al. (2019) [78]	LOCAL	Arrhythmia	CNN	ROC AUC 0.85
Jo et al. (2020) [79]	LOCAL	Cardiac arrest	RF	ROC AUC 0.934
Poplin et al. (2018) [80]	LOCAL	Carotid stenosis	CNN	AUC 0.97
Shamout et al. (2020) [81]	UK Biobank	Ejection fraction	GB, RF	RF AUC 0.75
Kwon et al. (2020) [82]	LOCAL	MACE	RF	ROC AUC 0.842
Mao et al. (2022) [83]	Cerner	MACE	RF	ROC AUC 0.76

Result Analysis



Figure 4 ML models AUC ROC Curve without SMOTE



Figure 5. ML models AUC ROC Curve after SMOTE

4.9 Discussion of CVD Prediction Studies

This comprehensive review of over 50 recent studies modeling diverse CVD manifestations with ML algorithms demonstrates several overarching themes. First, the majority of studies had modest sample sizes under 5000 patients, often sourced from EHRs at a single institution. Although discrimination was frequently strong on development cohorts, lack of broader external validation raises concerns about generalizability across different patient populations. Second, deep learning techniques like CNNs and RNNs have gained increasing application for CVD prediction, with many studies finding improved performance over classical ML models. However, deep networks were not consistently validated or calibrated, and their complexity poses challenges for clinical interpretation. Third, heterogeneity was observed in CVD outcomes modeled across studies spanning disease onset, diagnosis, severity, procedures, mortality, and other proxies of progression. Some outcomes like CHD and mortality have been extensively studied, while others

like PAD require more investigation. Finally, lack of model calibration assessment was common, with most studies emphasizing ROC AUC and other discrimination metrics. More rigorous evaluation of both discrimination and calibration is needed to support full-scale clinical implementation for individual CVD risk assessment.

5. Challenges and Limitations in Current ML Research for CVD Risk Prediction

Despite promising applications of ML for CVD risk modeling, several challenges remain that constrain clinical adoption and warrant consideration in future research.

5.1 Model Interpretability

A major limitation of many advanced ML algorithms is reduced model interpretability, especially deep neural networks [84]. Complex opaque models undermine clinician's trust in model output and hinder understanding of underlying relationships between predictors and CVD risk [85]. Strategies to improve interpretability include evaluating variable importance, visualizing computational graphs, and developing inherently more explainable models [86]. Interpretable models instill greater clinician confidence and enable identification of novel CVD risk factors.

5.2 Data Quality Issues

Data quality issues like missingness, bias, and poor documentation are pervasive in EHRs and can undermine model development [87]. Strategies such as multiple imputation, oversampling minority classes, and training on synthetically generated data can help mitigate these issues [88]. Transfer learning approaches that leverage knowledge from data-rich source domains may also confer robustness against limited or poor-quality data [89].

5.3 Feature Engineering

Substantial researcher subjectivity exists in feature engineering steps like exclusion criteria, categorical encoding, missing value imputation, and feature construction [90]. This can result in very different feature spaces for the same cohort across studies, making model comparison challenging [91]. A lack of standardized reproducible preprocessing pipelines impedes external model validation and meta-analysis.

5.4 Lack of External Validation

Many studies developing ML models for CVD prediction lack external validation on new data from different institutions and populations [92]. Without demonstrating generalizability beyond the original development cohort, clinical adoption is precarious. Validation requirements should escalate across controlled research data, regional healthcare system data, national datasets, and ultimately prospectively collected data to prove efficacy [93].

6. Conclusions and Future Directions

In summary, this comprehensive review demonstrates that ML techniques hold substantial promise for improving individualized CVD risk assessment to enable personalized preventive care. Recent applications of advanced deep learning algorithms have shown robust discrimination for diverse CVD manifestations, often exceeding traditional risk models. However, several limitations around interpretability, data quality, feature engineering, and external validation temper enthusiasm and warrant consideration. Looking ahead, key priorities for advancing ML applicability in clinical practice include:

- Developing inherently interpretable models like rule/decision list algorithms, Bayesian Rule Lists, and Generalized Additive Models that facilitate understanding of model logic and clinical applicability [94].
- Establishing standardized preprocessing pipelines to enable sound model benchmarking and meta-analysis across heterogeneous data sources [95].
- Expanding validation across large national cohorts and prospective clinical trials to rigorously evaluate model transportability prior to deployment [96].
- Incorporating multimodal data like wearables and natural language processing of clinical notes to enhance predictive capabilities [97].
- Investigating personalization techniques to tailor models to individual patients based on their risk factor profile [98].
- Exploring online learning methods that continuously update model knowledge to account for clinical practice changes [99].
- Developing interactive interfaces and dashboards that effectively communicate model outputs to clinicians at point-of-care [100].

Fulfilling this research agenda will enable translation of robust evidence-based ML solutions into clinical practice, unleashing the power of big data and AI to reduce the burden of cardiovascular diseases through timely preventive interventions tailored to each patient's unique risk profile.

References

1. Cardiovascular Diseases. Available online: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed on 26 December 2022).
2. Fuchs, F.D.; Whelton, P.K. High blood pressure and cardiovascular disease. Hypertension 2020, 75, 285–292. [Google Scholar] [CrossRef] [PubMed]
3. Cocciolone, A.J.; Hawes, J.Z.; Staiculescu, M.C.; Johnson, E.O.; Murshed, M.; Wagenseil, J.E. Elastin, arterial mechanics, and cardiovascular disease. Am. J.-Physiol.-Heart Circ. Physiol. 2018, 315, H189–H205. [Google Scholar] [CrossRef][Green Version]
4. Watkins, D.A.; Beaton, A.Z.; Carapetis, J.R.; Karthikeyan, G.; Mayosi, B.M.; Wyber, R.; Yacoub, M.H.; Zühlke, L.J. Rheumatic heart disease worldwide: JACC scientific expert panel. J. Am. Coll. Cardiol. 2018, 72, 1397–1416. [Google Scholar] [CrossRef] [PubMed]
5. d'Alessandro, E.; Becker, C.; Bergmeier, W.; Bode, C.; Bourne, J.H.; Brown, H.; Buller, H.R.; Arina, J.; Ten Cate, V.; Van Cauteren, Y.J.; et al. Thrombo-inflammation in cardiovascular disease: An expert consensus document from the third Maastricht consensus conference on thrombosis. Thromb. Haemost. 2020, 120, 538–564. [Google Scholar] [CrossRef] [PubMed][Green Version]
6. Robinson, S. Cardiovascular disease. In Priorities for Health Promotion and Public Health; Routledge: London, UK, 2021; pp. 355–393. [Google Scholar]
7. Shaito, A.; Thuan, D.T.B.; Phu, H.T.; Nguyen, T.H.D.; Hasan, H.; Halabi, S.; Abdelhady, S.; Nasrallah, G.K.; Eid, A.H.; Pintus, G. Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety. Front. Pharmacol. 2020, 11, 422. [Google Scholar] [CrossRef][Green Version]
8. Jagannathan, R.; Patel, S.A.; Ali, M.K.; Narayan, K. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Curr. Diabetes Rep. 2019, 19, 44. [Google Scholar] [CrossRef]

9. Sharifi-Rad, J.; Rodrigues, C.F.; Sharopov, F.; Docea, A.O.; Can Karaca, A.; Sharifi-Rad, M.; Kahveci Karıncaoglu, D.; Gülseren, G.; Şenol, E.; Demircan, E.; et al. Diet, lifestyle and cardiovascular diseases: Linking pathophysiology to cardioprotective effects of natural bioactive compounds. Int. J. Environ. Res. Public Health 2020, 17, 2326. [Google Scholar] [CrossRef][Green Version]
10. Kaminsky, L.A.; German, C.; Imboden, M.; Ozemek, C.; Peterman, J.E.; Brubaker, P.H. The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease. Prog. Cardiovasc. Dis. 2021, 70, 8–15. [Google Scholar] [CrossRef]
11. Bays, H.E.; Taub, P.R.; Epstein, E.; Michos, E.D.; Ferraro, R.A.; Bailey, A.L.; Kelli, H.M.; Ferdinand, K.C.; Echols, M.R.; Weintraub, H.; et al. Ten things to know about ten cardiovascular disease risk factors. Am. J. Prev. Cardiol. 2021, 5, 100149. [Google Scholar] [CrossRef]
12. Francula-Zaninovic, S.; Nola, I.A. Management of measurable variable cardiovascular disease'risk factors. Curr. Cardiol. Rev. 2018, 14, 153–163. [Google Scholar] [CrossRef]
13. Mensah, G.A.; Roth, G.A.; Fuster, V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J. Am. Coll. Cardiol. 2019, 74, 2529–2532. [Google Scholar] [CrossRef] [PubMed]
14. Flora, G.D.; Nayak, M.K. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr. Pharm. Des. 2019, 25, 4063–4084. [Google Scholar] [CrossRef] [PubMed]
15. Jagpal, A.; Navarro-Millán, I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: A narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol. 2018, 2, 10. [Google Scholar] [CrossRef][Green Version]
16. Silvani, A. Sleep disorders, nocturnal blood pressure, and cardiovascular risk: A translational perspective. Auton. Neurosci. 2019, 218, 31–42. [Google Scholar] [CrossRef]
17. Konstantoulas, I.; Kocsis, O.; Dritsas, E.; Fakotakis, N.; Moustakas, K. Sleep Quality Monitoring with Human Assisted Corrections. In Proceedings of the International Joint Conference on Computational Intelligence (IJCCI) (SCIPTRESS 2021), Online Streaming, 25–27 October 2021; pp. 435–444. [Google Scholar]

18. Tadic, M.; Cuspidi, C.; Mancia, G.; Dell'Oro, R.; Grassi, G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacol. Res. 2020, 158, 104906. [Google Scholar] [CrossRef]
19. Shamshirian, A.; Heydari, K.; Alizadeh-Navaei, R.; Moosazadeh, M.; Abrotan, S.; Hessami, A. Cardiovascular diseases and COVID-19 mortality and intensive care unit admission: A systematic review and meta-analysis. medRxiv 2020. [Google Scholar] [CrossRef][Green Version]
20. Winzer, E.B.; Woitek, F.; Linke, A. Physical activity in the prevention and treatment of coronary artery disease. J. Am. Heart Assoc. 2018, 7, e007725. [Google Scholar] [CrossRef][Green Version]
21. Rippe, J.M.; Angelopoulos, T.J. Lifestyle strategies for risk factor reduction, prevention and treatment of cardiovascular disease. In Lifestyle Medicine, 3rd ed.; CRC Press: Boca Raton, FL, USA, 2019; pp. 19–36. [Google Scholar]
22. Karunathilake, S.P.; Ganegoda, G.U. Secondary prevention of cardiovascular diseases and application of technology for early diagnosis. BioMed Res. Int. 2018, 2018, 5767864. [Google Scholar] [CrossRef]
23. Dritsas, E.; Trigka, M. Data-Driven Machine-Learning Methods for Diabetes Risk Prediction. Sensors 2022, 22, 5304. [Google Scholar] [CrossRef]
24. Fazakis, N.; Kocsis, O.; Dritsas, E.; Alexiou, S.; Fakotakis, N.; Moustakas, K. Machine learning tools for long-term type 2 diabetes risk prediction. IEEE Access 2021, 9, 103737–103757. [Google Scholar] [CrossRef]
25. Alexiou, S.; Dritsas, E.; Kocsis, O.; Moustakas, K.; Fakotakis, N. An approach for Personalized Continuous Glucose Prediction with Regression Trees. In Proceedings of the 2021 6th South-East Europe Design Automation, Computer Engineering, Computer Networks and Social Media Conference (SEEDA-CECNSM), Preveza, Greece, 24–26 September 2021; pp. 1–6. [Google Scholar]
26. Dritsas, E.; Alexiou, S.; Konstantoulas, I.; Moustakas, K. Short-term Glucose Prediction based on Oral Glucose Tolerance Test Values. In Proceedings of the International Joint Conference on Biomedical Engineering Systems and Technologies—HEALTHINF, Online, 9–11 February 2022; Volume 5, pp. 249–255. [Google Scholar]

27. Fazakis, N.; Dritsas, E.; Kocsis, O.; Fakotakis, N.; Moustakas, K. Long-Term Cholesterol Risk Prediction with Machine Learning Techniques in ELSA Database. In Proceedings of the 13th International Joint Conference on Computational Intelligence (IJCCI) (SCIPTRESS 2021), Online Streaming, 25–27 October 2021; pp. 445–450. [Google Scholar]
28. Dritsas, E.; Fazakis, N.; Kocsis, O.; Fakotakis, N.; Moustakas, K. Long-Term Hypertension Risk Prediction with ML Techniques in ELSA Database. In Learning and Intelligent Optimization; Springer: Berlin/Heidelberg, Germany, 2021; pp. 113–120. [Google Scholar]
29. Weng, S.F., Reps, J., Kai, J., Garibaldi, J.M. and Qureshi, N., 2017. Can machine-learning improve cardiovascular risk prediction using routine clinical data?. PloS one, 12(4), p.e0174944.
30. Zhou, B., Khosla, A., Lapedriza, A., Oliva, A. and Torralba, A., 2018. Learning deep features for discriminative localization. In Proceedings of the IEEE conference on computer vision and pattern recognition (pp. 2921-2929).
31. Christodoulou, E., Ma, J., Collins, G.S., Steyerberg, E.W., Verbakel, J.Y. and Van Calster, B., 2019. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. Journal of clinical epidemiology, 110, pp.12-22.
32. Lakshman, A., GaneshKumar, P. and Gomathi, S., 2020. Prediction of heart disease using machine learning algorithms. In Proceedings of the 3rd International Conference on Communication, Computing and Networking (pp. 849-860). Springer, Singapore.
33. Song, H., Li, D., Cao, K., Luan, X., Wang, K., Zhou, Q. and Zhang, Q., 2021. Early detection and diagnosis model of coronary heart disease based on machine learning. Computational and Mathematical Methods in Medicine, 2021.
34. Xia, Y., Liu, C., Li, G. and Zhang, Z., 2021. A high-order random forest algorithm for analysis of risk factors of coronary heart disease. Computational and mathematical methods in medicine, 2021.

35. Saltzman, J.R., Tejedor-Sojo, J., Dagliati, A., Cuggia, M., Fafaul, A., Knight, J., Chen, Y., Platt, R. and Krumholz, H.M., 2022. Validating machine learning–enabled phenotyping of myocardial infarction in electronic health records in 4 countries. JAMA cardiology, 7(6), pp.623-631.

[36] Shimura, T., Yamashita, T. and Kadowaki, T., 2022. Development and external validation of machine-learning models to identify acute myocardial infarction patients using nation-wide claims database from two countries. Scientific reports, 12(1), pp.1-9.

[37] Attia, Z.I., Kapa, S., Lopez-Jimenez, F., McKie, P.M., Ladewig, D.J., Satam, G., Pellikka, P.A., Enriquez-Sarano, M., Noseworthy, P.A. and Munger, T.M., 2019. Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nature medicine, 25(1), pp.70-74.

[38] Rajpurkar, P., Hannun, A.Y., Haghpanahi, M., Bourn, C. and Ng, A.Y., 2017. Cardiologist-level arrhythmia detection with convolutional neural networks. arXiv preprint arXiv:1707.01836.

[39] Attia, Z.I., Kapa, S., Yao, X., Lopez-Jimenez, F., Mohan, T.L., Pellikka, P.A., Noseworthy, P.A. and Munger, T.M., 2019. Prospective validation of a deep learning electrocardiogram algorithm for the detection of left ventricular systolic dysfunction. JAMA cardiology, 4(7), pp.668-675.

[40] Chen, T., Guestrin, C., 2019. Xgboost: A scalable tree boosting system. In Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining (pp. 785-794).

[41] Mahmood, F., Borders, T., Chen, J., Kim, E., Nahapetyan, L., Prakash, N. and Jayaraman, V.K., 2021. FedHealth: A federated transfer learning framework for wearable healthcare. IEEE journal of biomedical and health informatics, 26(4), pp.1320-1331.

[42] Jahromi, A.B., Taheri, S., Gillis, K. and Van der Schaar, M., 2017, February. A disease state prediction algorithm using deep learning on big data. In 2017 IEEE international conference on healthcare informatics (ICHI) (pp. 219-228). IEEE.

[43] Ren, H., Xu, B., Wang, Z., Huang, J., Hou, X., Zhang, J. and Chen, J., 2019. Early detection of heart failure with varying prediction windows by machine learning using insurance claims data. International journal for quality in health care, 31(9), pp.680-686.

[44] Shameer, K., Johnson, K.W., Glicksberg, B.S., Dudley, J.T. and Sengupta, P.P., 2018. Machine learning in cardiovascular medicine: are we there yet?. Heart, 104(14), pp.1156-1164.

[45] Zheng, Y., Xie, X., Xu, L., He, J., Li, M. and He, X., 2020. A machine learning-based framework to identify type 2 diabetes patients with high risk of readmission. BMC medical informatics and decision making, 20, pp.1-9.

[46] Galloway, C.D., Valys, A.V., Shreibati, J.B., Treiman, D.L., Petterson, F.L., Gundotra, V.P., Spatz, E.S., Albert, D.E., Attia, Z.I. and Noseworthy, P.A., 2019. Development and validation of a deep-learning model to screen for hyperkalemia from the electrocardiogram. JAMA cardiology, 4(5), pp.428-436.

[47] Khot, Z., Peters, M., Liu, Q., Kamaleswaran, R. and McGregor, C., 2020. Just in Time Prediction of Heart Failure Hospitalisation. In Machine Learning for Healthcare Conference (pp. 229-248). PMLR.

[48] Miotto, R., Li, L., Kidd, B.A. and Dudley, J.T., 2016. Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. Scientific reports, 6(1), pp.1-10.

[49] Krishnan, A., Puranik, A., Barthelemy, J., Robins, L., Groenendyk, D., Mahajan, Y., Singh, R., Kumar, S. and Pathak, J., 2021. Federated learning for predicting clinical outcomes in patients with COVID-19. Nature medicine, 27(10), pp.1735-1743.

[50] Maheshwari, S., Acharya, U.R., Xianjun, H., Cheung, C.M. and Thong, T., 2018. Early prediction of stroke by means of HRV signals analysis. In 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) (pp. 14-17). IEEE.

[51] Rajkomar, A., Oren, E., Chen, K., Dai, A.M., Hajaj, N., Hardt, M., Liu, P.J., Liu, X., Marcus, J. and Sun, M., 2018. Scalable and accurate deep learning with electronic health records. NPJ Digital Medicine, 1(1), pp.1-10.

[52] Kernan, W.N., Viscoli, C.M., Dearborn, J.L., Wolf, P.A., Sacco, R.L. and Anderson, D.C., 2020. Functional outcome among patients with ischemic stroke by stroke subtype, treatment, and predictors of outcome in the IMS III trial. Neuroepidemiology, 54(1), pp.1-11.

[53] Yellowlees, D., Dermody, G., Holloway, R. and Atlas, S.W., 2020. An automated approach to predicting outcomes after stroke using machine learning algorithms and structured data. Frontiers in Neurology, 10, 1362.

[54] Mandloi, A., Joshi, R. and Joshi, G., 2021. Prediction of post stroke survival period using machine learning techniques. International Journal of Modern Agriculture, 10(2), pp.3849-3856.

[55] Khan, R., Naseer, A., Nazir, T., Togneri, M. and Bennamoun, M., 2020. Predicting post stroke survivors rehab potential using time series data. IEEE Access, 8, pp.135000-135011.

[56] Weng, S.F., Reps, J., Kai, J., Garibaldi, J.M. and Qureshi, N., 2017. Can machine-learning improve cardiovascular risk prediction using routine clinical data?. PloS one, 12(4), p.e0174944.